(Q36466260)

14 August 2017

1 reference

title

Recent clinical experience with dronabinol (English)

1 reference

14 August 2017

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

24 October 2022

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

24 October 2022

author name string

T. F. Plasse

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1666930

24 October 2022

R. W. Gorter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1666930

24 October 2022

S. H. Krasnow

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1666930

24 October 2022

M. Lane

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1666930

24 October 2022

K. V. Shepard

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1666930

24 October 2022

R. G. Wadleigh

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1666930

24 October 2022

language of work or name

English

0 references

publication date

1 November 1991

1 reference

full work available at URL

14 August 2017

https://api.elsevier.com/content/article/PII:009130579190385F?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

https://api.elsevier.com/content/article/PII:009130579190385F?httpAccept=text/plain

24 October 2022

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Pharmacology, Biochemistry and Behavior

24 October 2022

published in

1 reference

14 August 2017

40

1 reference

14 August 2017

695-700

1 reference

14 August 2017

3

1 reference

Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain

14 August 2017

2

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy

24 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation

24 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

24 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy

24 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo

24 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Isolation and structure of .DELTA.+- tetrahydrocannabinol and other neutral cannabinoids from hashish

24 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Neuropharmacological study of 9 - and 8 -L-tetrahydrocannabinols in monkeys and mice.

24 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study

24 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Δ9-Tetrahydrocannabinol for Refractory Vomiting Induced by Cancer Chemotherapy

24 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy

24 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis

24 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine

24 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Cancer therapy, vomiting, and antiemetics.

24 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

Cannabis and cancer chemotherapy. A comparison of oral delta-9-thc and prochlorperazine

24 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90385-F

24 October 2022

Identifiers

1 reference

14 August 2017

1 reference